Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 19, 2025Journal of Pharmaceutical Research International

Optimizing Migraine Therapy: A Comparative Review of Dosage and Tolerability of Calcitonin Gene Related Peptide Antagonists

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSarabjot Singh MakkarPAParinita ArooriLGLeela Sarmada Gaddamanugu

Discussion

Loading...

Member takes

Overview

This review evaluates the dosage and tolerability of CGRP inhibitors in migraine management, highlighting therapeutic strategies.

Key Points

  • CGRP inhibition reduces overall monthly migraine days, improving patient quality of life with effective therapy.
  • Monoclonal antibodies are administered monthly or quarterly, providing favourable tolerability despite mild side effects.
  • Gepants are available in oral and nasal forms for migraine treatment, demonstrating moderate tolerability with specific adverse effects.
  • CGRP-targeted therapies offer individualised treatment options, enhancing flexibility in migraine management strategies.

Cite This Study

Makkar et al. (2025) studied this question.

synapsesocial.com/papers/68d46fc631b076d99fa69a36https://doi.org/10.9734/jpri/2025/v37i97742
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preventive Treatment of Migraine2024 · 15 citations
  2. 2CGRP Inhibitor Use In Migraine Treatments2024
  3. 3Developments in targeting calcitonin gene-related peptide2024 · 9 citations
  4. 4CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025 · 15 citations
  5. 5CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025